Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

Benzinga · 4d ago
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $45 to $50.